Sera Prognostics Inc-a (SERA)

$10.01

+0.05

(+0.5%)▲

Live

Insights on Sera Prognostics Inc-a

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 123.0K → 41.0K (in $), with an average decrease of 34.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -7.21M → -7.92M (in $), with an average decrease of 9.9% per quarter

Performance

  • $9.69
    $10.22
    $10.01
    downward going graph

    3.2%

    Downside

    Day's Volatility :5.19%

    Upside

    2.05%

    downward going graph
  • $1.52
    $11.32
    $10.01
    downward going graph

    84.82%

    Downside

    52 Weeks Volatility :86.57%

    Upside

    11.57%

    downward going graph

Returns

PeriodSera Prognostics Inc-aSector (Health Care)Index (Russel 2000)
3 Months
67.96%
1.9%
0.0%
6 Months
503.64%
10.7%
0.0%
1 Year
197.31%
4.6%
-1.1%
3 Years
-16.3%
14.2%
-22.1%

Highlights

Market Capitalization
316.8M
Book Value
$2.21
Earnings Per Share (EPS)
-1.16
Wall Street Target Price
2.75
Profit Margin
0.0%
Operating Margin TTM
-21580.49%
Return On Assets TTM
-23.51%
Return On Equity TTM
-42.86%
Revenue TTM
306.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-36.9%
Gross Profit TTM
75.0K
EBITDA
-38.9M
Diluted Eps TTM
-1.16
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.01
EPS Estimate Next Year
-0.97
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Sera Prognostics Inc-a(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 72.53%

Current $10.01
Target $2.75

Company Financials

FY19Y/Y Change
Revenue
36.0K
-
Net Income
-20.4M
-
Net Profit Margin
-56.8K%
-
FY20Y/Y Change
Revenue
25.0K
↓ 30.56%
Net Income
-21.6M
↑ 5.71%
Net Profit Margin
-86.4K%
↓ 29653.0%
FY21Y/Y Change
Revenue
82.0K
↑ 228.0%
Net Income
-36.2M
↑ 67.67%
Net Profit Margin
-44.2K%
↑ 42247.51%
FY22Y/Y Change
Revenue
268.0K
↑ 226.83%
Net Income
-44.2M
↑ 22.13%
Net Profit Margin
-16.5K%
↑ 27670.42%
FY23Y/Y Change
Revenue
306.0K
↑ 14.18%
Net Income
-36.2M
↓ 18.09%
Net Profit Margin
-11.8K%
↑ 4666.28%
Q3 FY22Q/Q Change
Revenue
87.0K
↑ 11.54%
Net Income
-10.2M
↓ 9.88%
Net Profit Margin
-11.7K%
↑ 2780.64%
Q4 FY22Q/Q Change
Revenue
65.0K
↓ 25.29%
Net Income
-9.8M
↓ 3.85%
Net Profit Margin
-15.1K%
↓ 3356.53%
Q1 FY23Q/Q Change
Revenue
100.0K
↑ 53.85%
Net Income
-9.8M
↑ 0.32%
Net Profit Margin
-9.8K%
↑ 5238.38%
Q2 FY23Q/Q Change
Revenue
123.0K
↑ 23.0%
Net Income
-10.5M
↑ 7.39%
Net Profit Margin
-8.6K%
↑ 1246.27%
Q3 FY23Q/Q Change
Revenue
42.0K
↓ 65.85%
Net Income
-7.2M
↓ 31.61%
Net Profit Margin
-17.2K%
↓ 8595.94%
Q4 FY23Q/Q Change
Revenue
41.0K
↓ 2.38%
Net Income
-7.9M
↑ 9.92%
Net Profit Margin
-19.3K%
↓ 2162.6%
FY19Y/Y Change
Total Assets
23.3M
-
Total Liabilities
129.9M
-
FY20Y/Y Change
Total Assets
14.8M
↓ 36.39%
Total Liabilities
140.4M
↑ 8.07%
FY21Y/Y Change
Total Assets
147.0M
↑ 893.71%
Total Liabilities
8.5M
↓ 93.97%
FY22Y/Y Change
Total Assets
116.3M
↓ 20.88%
Total Liabilities
17.4M
↑ 105.39%
FY23Y/Y Change
Total Assets
95.4M
↓ 17.96%
Total Liabilities
25.3M
↑ 45.42%
Q3 FY22Q/Q Change
Total Assets
116.6M
↓ 6.79%
Total Liabilities
9.4M
↑ 15.35%
Q4 FY22Q/Q Change
Total Assets
116.3M
↓ 0.2%
Total Liabilities
17.4M
↑ 84.92%
Q1 FY23Q/Q Change
Total Assets
105.6M
↓ 9.21%
Total Liabilities
15.4M
↓ 11.42%
Q2 FY23Q/Q Change
Total Assets
96.7M
↓ 8.46%
Total Liabilities
15.5M
↑ 0.93%
Q3 FY23Q/Q Change
Total Assets
90.1M
↓ 6.85%
Total Liabilities
14.6M
↓ 5.77%
Q4 FY23Q/Q Change
Total Assets
95.4M
↑ 5.98%
Total Liabilities
25.3M
↑ 72.63%
FY19Y/Y Change
Operating Cash Flow
-19.3M
-
Investing Cash Flow
-6.0K
-
Financing Cash Flow
33.0M
-
FY20Y/Y Change
Operating Cash Flow
-16.9M
↓ 12.71%
Investing Cash Flow
-149.0K
↑ 2383.33%
Financing Cash Flow
9.2M
↓ 72.28%
FY21Y/Y Change
Operating Cash Flow
-31.6M
↑ 87.55%
Investing Cash Flow
-82.6M
↑ 55308.72%
Financing Cash Flow
159.6M
↑ 1642.29%
FY22Y/Y Change
Operating Cash Flow
-34.6M
↑ 9.4%
Investing Cash Flow
5.6M
↓ 106.72%
Financing Cash Flow
5.0K
↓ 100.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-8.8M
↓ 2.89%
Investing Cash Flow
-6.3M
↑ 420.76%
Financing Cash Flow
-8.0K
↓ 113.79%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.2M
↓ 17.53%
Investing Cash Flow
-1.6M
↓ 74.94%
Financing Cash Flow
-116.0K
↑ 1350.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.9M
↓ 32.56%
Investing Cash Flow
2.3M
↓ 247.02%
Financing Cash Flow
-116.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↑ 62.84%
Investing Cash Flow
12.9M
↑ 456.38%
Financing Cash Flow
124.0K
↓ 206.9%

Technicals Summary

Sell

Neutral

Buy

Sera Prognostics Inc-a is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sera Prognostics Inc-a
Sera Prognostics Inc-a
8.85%
503.64%
197.31%
-16.3%
-16.3%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.78%
14.63%
-1.95%
-11.57%
119.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-4.37%
31.77%
0.52%
1.35%
83.67%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.18%
25.39%
0.05%
16.3%
119.68%
Danaher Corp.
Danaher Corp.
2.14%
28.59%
-0.49%
-1.93%
95.75%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-4.12%
27.82%
17.55%
2.23%
75.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sera Prognostics Inc-a
Sera Prognostics Inc-a
NA
NA
NA
-1.01
-0.43
-0.24
NA
2.21
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.62
47.62
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.04
32.04
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.47
35.47
2.81
21.55
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
41.86
41.86
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.69
32.69
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sera Prognostics Inc-a
Sera Prognostics Inc-a
Buy
$316.8M
-16.3%
NA
0.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.8B
119.88%
47.62
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.2B
83.67%
32.04
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$209.3B
119.68%
35.47
13.99%
Danaher Corp.
Danaher Corp.
Buy
$174.8B
95.75%
41.86
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.4B
75.73%
32.69
9.06%

Institutional Holdings

  • Baker Bros Advisors LP

    16.76%

  • InterWest Venture Management Co

    7.45%

  • Vivo Capital, LLC

    5.09%

  • Vanguard Group Inc

    2.80%

  • CapTrust Financial Advisors

    1.23%

  • Awm Investment Company Inc

    1.16%

Corporate Announcements

  • Sera Prognostics Inc-a Earnings

    Sera Prognostics Inc-a’s price-to-earnings ratio stands at None

    Read More

Company Information

sera prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. the company has assembled a strong management team and board of directors with significant clinical development and women’s healthcare diagnostic experience. the company is supported by a strong group of investors, including the bill & melinda gates foundation, chione, ltd, domain associates, interwest partners, catalyst health ventures, upstart life sciences capital, and osage university partners. the company is working with the bill & melinda gates foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. sera prognostics is located in salt lake city, utah. sera launched its first diagnos

Organization
Sera Prognostics Inc-a
Employees
55
CEO
Ms. Evguenia Lindgardt M.B.A.
Industry
Services

Discover More

FAQs